A detailed history of Gratus Capital LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Gratus Capital LLC holds 3,539 shares of GILD stock, worth $299,364. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,539
Previous 3,245 9.06%
Holding current value
$299,364
Previous $237,000 2.11%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$63.15 - $72.88 $18,566 - $21,426
294 Added 9.06%
3,539 $242,000
Q1 2024

May 13, 2024

BUY
$71.58 - $87.29 $232,277 - $283,256
3,245 New
3,245 $237,000
Q2 2021

Aug 10, 2021

SELL
$63.47 - $69.35 $265,368 - $289,952
-4,181 Closed
0 $0
Q1 2021

May 04, 2021

SELL
$60.0 - $68.46 $7.24 Million - $8.26 Million
-120,603 Reduced 96.65%
4,181 $270,000
Q4 2020

Feb 03, 2021

BUY
$56.65 - $64.55 $7.07 Million - $8.05 Million
124,784 New
124,784 $7.27 Million
Q1 2020

May 01, 2020

SELL
$62.63 - $80.22 $6.52 Million - $8.35 Million
-104,053 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$61.62 - $67.78 $90,766 - $99,839
1,473 Added 1.44%
104,053 $6.76 Million
Q3 2019

Oct 30, 2019

SELL
$62.51 - $69.0 $3.06 Million - $3.38 Million
-48,978 Reduced 32.32%
102,580 $6.5 Million
Q4 2018

Feb 13, 2019

BUY
$60.54 - $79.0 $9.18 Million - $12 Million
151,558 New
151,558 $247,000
Q4 2017

Feb 07, 2018

SELL
$71.15 - $83.52 $190,895 - $224,084
-2,683 Closed
0 $0
Q3 2017

Nov 09, 2017

BUY
$72.11 - $85.47 $193,471 - $229,316
2,683
2,683 $217,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $106B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Gratus Capital LLC Portfolio

Follow Gratus Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gratus Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gratus Capital LLC with notifications on news.